Integrum AB (publ)

OM:INTEG B Stock Report

Market Cap: SEK 190.5m

Integrum Past Earnings Performance

Past criteria checks 0/6

Integrum's earnings have been declining at an average annual rate of -48.7%, while the Medical Equipment industry saw earnings growing at 22.3% annually. Revenues have been growing at an average rate of 20.1% per year.

Key information

-48.75%

Earnings growth rate

-45.70%

EPS growth rate

Medical Equipment Industry Growth6.16%
Revenue growth rate20.05%
Return on equity-19.02%
Net Margin-29.10%
Next Earnings Update02 Mar 2026

Recent past performance updates

Recent updates

Revenues Tell The Story For Integrum AB (publ) (STO:INTEG B) As Its Stock Soars 99%

Jul 23
Revenues Tell The Story For Integrum AB (publ) (STO:INTEG B) As Its Stock Soars 99%

We're Hopeful That Integrum (STO:INTEG B) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Integrum (STO:INTEG B) Will Use Its Cash Wisely

Market Might Still Lack Some Conviction On Integrum AB (publ) (STO:INTEG B) Even After 26% Share Price Boost

May 22
Market Might Still Lack Some Conviction On Integrum AB (publ) (STO:INTEG B) Even After 26% Share Price Boost
User avatar

US Sales Focus And Axor II Will Boost Market Outlook

Strategic focus on U.S. market growth and marketing optimization is expected to boost revenue and improve net margins.

We're Not Very Worried About Integrum's (STO:INTEG B) Cash Burn Rate

Dec 05
We're Not Very Worried About Integrum's (STO:INTEG B) Cash Burn Rate

Slammed 38% Integrum AB (publ) (STO:INTEG B) Screens Well Here But There Might Be A Catch

Aug 30
Slammed 38% Integrum AB (publ) (STO:INTEG B) Screens Well Here But There Might Be A Catch

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

May 03
We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

Sep 20
Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

Revenue & Expenses Breakdown

How Integrum makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:INTEG B Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Oct 25103-301090
31 Jul 25103-311130
30 Apr 2598-311100
31 Jan 2597-201070
31 Oct 24105-151000
31 Jul 24115-2920
30 Apr 241104880
31 Jan 24100-4860
31 Oct 2387-19850
31 Jul 2374-18880
30 Apr 2378-16850
31 Jan 2381-7840
31 Oct 22767750
31 Jul 226619650
30 Apr 226121550
31 Jan 225216460
31 Oct 214916410
31 Jul 21492390
30 Apr 2144-2350
31 Jan 2139-4350
31 Oct 2035-9360
31 Jul 2031-14360
30 Apr 2028-16380
31 Jan 2023-20410
31 Oct 1921-24440
31 Jul 1925-24450
30 Apr 1926-25460
31 Jan 1926-23440
31 Oct 1822-23400
31 Jul 1817-23370
30 Apr 1819-18340
31 Jan 1820-17330
31 Oct 1724-10310
31 Jul 1722-9280
30 Apr 1723-6260
31 Jan 17240210
30 Apr 16180160
30 Apr 15170140

Quality Earnings: INTEG B is currently unprofitable.

Growing Profit Margin: INTEG B is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: INTEG B is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.

Accelerating Growth: Unable to compare INTEG B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INTEG B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-29.3%).

Return on Equity

High ROE: INTEG B has a negative Return on Equity (-19.02%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/24 22:20
End of Day Share Price 2025/11/24 00:00
Earnings2025/10/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Integrum AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerDNB Carnegie Commissioned Research
Oscar BergmanRedeye